DOCSLIB.ORG

Bahrain-Pharma-1444108170.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Fill Type of Competition S. No BP Brand Name Therapeutical Class Potency Generic Name/Composition Volume Dosage Name,company, retail price form Each 5 ml contents: Samol 120 ml Salbutamol Sulphate 2mg Salbutamol 1 Anti-Asthmatic agent (Bronchodilator) Each 5ml contains Acefylline piperazine 125mg Pifalin 100 ml Acefylline Piperazine 2 (125mg/5ml) Acefylline Piperazine 45mg, Diphenhydramine Dephicef 100 ml Acefylline Piperazine + Diphenhydramine 3 8mg/5ml Ammonium Chloride 100.00mg , Sodium Clomadrin 100 ml Citrate 60.00mg, Ephedrine HCl 7.00mg, Ammonium Chloride + Sodium Citrate + Ephedrine HCl + Chlorpheniramine Maleate 4 Chlorpheniramine Maleate 2.00mg/5ml Each 5 ml contents: Ambroxol HCl eq. to 100 ml Ambroxol 15mg 5 Ambrol Ambroxol HCl Each 5 ml contents: Ambroxol HCl eq. to Cough and Cold 100 ml Syrup 6 Ambroxol 30mg 7 Dextron 100 ml 15mg/5 ml Dextromethorphan Hbr 8 Gufosil 100 ml 100mg/5 ml Guaifenesin 9 Proligen 120 ml 1.25mg + 30mg/5 ml Triprolodin HCl + Pseudoephedrine HCl 10 Tripodil 120 ml 1.25mg + 30mg + 10mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr 11 Tripogin 120 ml 1.25mg + 30mg + 100 mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Guaifenesin 12 Dexotrin 120 ml 1.25mg +10mg + 7.5mg + 50mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr + Guaifenesin Wild cherry (Prunus serotina) + (myroxylon balsamum) + Mallow (Malva Sylvestris) + Welcosin 120 ml 60mg + 18.75mg + 7.5mg + 7.5mg / 5ml 13 Marshnallow (Althaea officinalis) 14 Ivosil 100 ml Each 5 ml contents: Ivy leaf 15 Hexobim 100 ml 4mg/5mlIvy leaves dried extract (4-8:1, 100%) 100 mg Bromhexine HCl Carbocisteine 2% and 5% (i.e. 2gm/100 ml & Bocarist 100 ml Carbocisteine 16 Mucolytic Agents 5gm/100 ml) Carbocisteine 2% & Promethazine HCl 0.05% 17 Thyprozin 100 ml Carbocisteine & Promethazine HCl (i.e. 2gm+0.05gm/100 ml) 18 Maglunil Antacid 100 ml Suspension 405mg + 100mg/5 ml Dried Aluminium hydroxide & Magnesium Hydroxide Anti-tussive / Aminophylline 30mg , Ammonium Chloride 19 Difocil Astringent, 100 ml Aminophylline/Ammonium Chloride Diphenhydramine 30mg, Diphenhydramine Hcl 8mg / 5ml Anti-histamine Ammonium Chloride 100mg, Astringent/Anti- 20 Chlormol 100 ml Chlorpheneramine Maleate 2mg, Sodium Ammonium Chloride + Chloropheneramine maleate histamine Citrate 60mg, Menthol 1mg/5ml Calcium Carbonate 160mg + Vitamin D3 160IU 21 Calcip Dietary Supplement 100 ml Calcium Carbonate + Vitamin D3 / 5ml Dextromethorphan hydrobromide 6mg, 22 Dexopan 100 ml Dextromethorphan + Diphenhydramine Dry Cough DiphenhydramineHcl 5mg/5ml 23 Dalfopen 100 ml Diphenhydramine 15mg /5ml Diphenhydramine Iron Protein Succinylate equivalent to Ironil 100 ml 24 Elemental Iron: 40mg/5ml Elemental Iron Iron Protein Succinylate equivalent to 25 Prosital 100 ml Iron Supplement Elemental Iron: 50mg Folic Acid: 0.35mg/5ml Felonic 100 ml Each 100 ml Contains: 900mg + 10mg + 20mg Ferric Ammonium Citrate + Folic Acid + Multi Vitamin (B1 + B6 + nicotinamde) 26 + 40ml + 200mg Melofin 100 ml Iron III hydroxide Polymaltose 50mg Elemental Iron (III) hydroxide Polymaltose 27 Iron/ 5ml Syrup Isonaz Anti-tuberculosis 100 ml 50mg /5ml Isoniazid 28 Ivy leaf extract 35mg, Glycyrhhiza Glabra 25mg Ivogil 100 ml Ivy leaf + Glycyrhhiza Glabra 29 Cough/Astringent / 5ml Ivothin 100 ml Ivy leaf extract 35mg, Glycyrhhiza glabra 25mg, Ivy leaf + Thyme + Glycyrhhiza Glabra 30 Thyme liquid extract 250mg / 5ml Cartil Muscle 100 ml 500mg/5 ml L-Carnitine 31 Each 15 ml syrup contains: Lactulose 10 g Laxilol Laxative 250 ml Lactulose 32 added as Lactulose concentrate. Anti- Lovas 100 ml 50mg/l5ml Levamisole HCl 33 helmintic/Immunomod ulator 34 Lorasip 100 ml 5mg/5ml Loratidine 35 Levodic 100 ml 5mg/5ml Levocetirizine Di HCl Anti histamine 36 Cetzomin 100 ml 5mg/5ml Cetirizine Dihydrochloride 37 Dorasip 100 ml 0.5mg/ml Desloratidine 38 100 ml 50mg/5ml Mefadoz Mefenamic Acid 39 NASIDs 100 ml 100mg/5ml 40 Ifrocen 100 ml Suspension 100mg/5ml Ibuprofen 41 Mecoprim 100 ml Syrup 5mg/ 5ml Metoclopramide Anti-emetic 42 Doparid 100 ml 1mg /ml Domperidone Anti-biotic Metodil 100 ml 200mg/5ml Metronidazole 43 (Nitroimidazole) 44 100 ml 12mg/5ml Paragol Analgesic Paracetamol 45 100 mlSuspension 250mg/5ml Each 5ml contents: Pelargonium root dried extract (16-25:1,10% ) Pelargin Bronchitis 100 ml Pelargonium root 130mg 46 Rispaden Anticonvulsant/Antipsy 100 ml 1mg/5ml Risperidone 47 chotic 48 Valposil 100 ml 200mg/5ml Sodium Valproate 49 Sufad Anti-Ulcer 100 ml 1gm/5ml Sucralfate 75mg + 18 mg +1mg + 1.66mg + 4.16mg + 8.33 Ascorbic Acid + Nicotinamide + Pyridoxine HCl + Riboflavin 5 –Phosphate sodium + Thiamine Ribnocal 200 ml mcg + 33.33mg + 5mg + 2.5mg/5ml HCl + Cyanocobalamine + Lysine Monohydrochloride + inositol + Calcium D-Pentothenate 50 450mg + 10000IU + 2000ppm (2000Ug/gm)/ Keldavin 200 ml Calcium Carbonate + Vitamine D3 (Food grade) + Vitamin K2 (Menaquinone) 51 5ml 52 Omgobit 200 ml 150mg + 125mg + 5mg + 60mg / 5ml Choline Bitartrate + Omega 3 Powder + Vinpocetin + Ginkgo Biloba Extract Each 10ml Contents: Multi Vitamins (60mg + 1.4mg + 2.2mg + 18mg + 2mg + 400mcg + Multi Vitamins (Vitamin C + B1 + B2 + B3 + B6 + Folic acid + B12 + Pantothenic acid) + Mutli Syrup 2mcg + 8mg) + Mutli minerals (14mg + 15mg minerals (Iron + Zinc + Iodein + Lysine +calcium glcerophosphate + Pot. Glycerophosphate + Glycasip 200 ml Multivitamins/Multimi +150mcg + 200mg + 45mg + 45mg +23mg + Sod. Glycerophosphate +Ma. Glycerophosphate ) + Honey + Malt extract + Herbal nerals 0.3mg) + 220mg + 1000mg + Herbal preparations (Ginkgo Biloba leaf extract + Sarsaparilla ext + Birch Leaf) preparations (10mg + 10mg + 10mg) 53 5000IU + 500IU + 5mg + 2mg + 6mcg + 50mg + Ascobin 200 ml Multivitmains (Vitamin A + Vit D + B1 +B2 + B6 + Ascorbic acid + Nicotinamide) 20 mg 54 300mg + 3mg + 3.5mg + 6mg + 400IU + 15mg + Multivitamin (Lysin HCl + B1 + B2 + B6 + D3 + E + Nicotiamide + Dexpanthenol) + Mineral Bitnocin 200 ml 55 20mg + 10mg + 130 mg (Calcium) 1.5mg + 1mg + 1mg + 2.5mcg + 10mg+100mcg Multivitamin (Vit B1 +B2 +B6 + B12 + Niacinamide + Folic acid + D-Panthenol + Vit C) + Mifanol 200 ml + 2 mg + 25mg + 10mg + 10mg + 3mg + 0.25mg Mutiminerals (Cal. Glycerophosphate + Iron + Zinc + Magnesium + Copper + L-Lysine HCl) 56 + 0.20 mg +20mg 57 Osaril 200 ml Calcium 430mg/5ml Ossein Mineral Complex Therapeutic Competition S. No BP Brand Name Package type Strength Generic Name/Composition al Class Name,company, retail price 1 Krillinol botlle 500mg Krill Oil 2 Cratigron botlle 450mg Dried extract of Hawthorn flowers & Leaves 3 Uni-Qnol botlle 100mg Ubiquinol (CoQ10) 4 Vita-D3 botlle 200 IU Vitamin D3 (as cholecalciferol) 5 Vita-D3 botlle 5000 IU Vitamin D3 (as cholecalciferol) 6 Vita-D3 botlle 10000 IU Vitamin D3 (as cholecalciferol) 7 Linocon botlle 750mg Conjugated Linoleic acid 8 Curcunoid botlle 500mg Curcuminoids 9 Berican botlle 300mg Cranberry Extract 10 Glumax botlle 600mg Glucosamine 11 Segrap botlle 300mg Grape Seed Extract 12 Gretex botlle 500mg VITAMINS / Green tea extract 13 Haber-FX botlle 200mg + 200mg MINERALS / Hawthorn berry extract + Fish Roe NATRURAL 14 botlle 1000mg + 1IU Omega-3 Fish Oil + Vitamin E Feom-3 PRODUCTS / 15 Calmin-VD botlle 500IU + 600mg DIETARY Vitamin D3 + Calcium 16 Vitaran botlle 400IU SUPPLEMENTS Vitamin E 17 K-Vit botlle 10mg Vitamin K1 18 Evogam botlle 100mg Evening Primrose Oil 19 Evogam botlle 500mg Evening Primrose Oil 20 Evogam botlle 1000mg Evening Primrose Oil 21 Seafeol botlle 1000mg Salmon Oil 22 Olifix botlle 1000mg Fish Oil 23 Vinpogin botlle 5000mg Ginkgo biloba 24 Flixoid botlle 1000mg Flax Seed Oil (Linseed Oil) 25 Gikomin botlle 80mg + 200mg Ginkgobiloba + Vitamin E 26 Garax botlle 0.625mg Garlic oil 27 Livocod botlle 1000mg Codliver Oil 100mg + 200mg Complex vitamins 28 Betaplex botlle + 200mcg Vitamin-B Complex (B1 + B6 + B12) Korean ginseng 50.0mg + Royal Jelly 10mg + Retinol palmitate (Vitamin A) 2500 IU + Ergocalciferol 400 IU + dl-alpha-Tocopherol 45mg + B1 2mg + B2 2mg + B6 2mg + vit C 100mg + B3 20mg + calcium pantothenate 30mg + B12 6mcg + ferrous fumarate 27.38mg + copper sulphate 7.86mg + mg.oxide 66.34mg + zinc oxide 5mg + anhydrous dibasic calcium phosphate 29 Multizid 307.5mg + Mg. sulfate 3mg + Potassium sulfate 18mg Vitamin A 2000 IU + Vitamin D3 270 IU + B1 1mg + B2 1mg + B6 1.34mg + Nicotinamide 8mg + Calcium pantothenate 1mg + B12 1mcg + Vit C 33.3mg + Calcium 190mg + Phosporous 150mg + Iron 5mg + Copper 0.01mg + Iodine 0.0015mg + Magnesuim 1mg 30 Micnovit + Manganese 0.01mg + Potassium 1mg + Zinc 0.15mg Vitamin A 5000 IU + Vitamin D3 (Choleclaciferol) 200 IU + Vitamin E (tocopheryl acetate) 7.5mg + B1 2.5mg + B2 2.5mg + Nicotinamide 25mg + D-panthenol 2.5mg + B6 1mg + Vit C 40mg + Folic acid 500mcg + B12 2.5mcg + Dibasic calcium phosphate 35mg + Copper sulphate 0.1mg + Manganese sulphate 0.01mg + Zinc sulphate 50mg + Potassium iodide 0.025mg + 31 Mebopan Magnesium oxide 0.15mg Vitamin A (as palmitate) 2000 IU + B1 1mg + B2 1mg + B6 1.34mg + B12 1mcg + D3 200 IU + Vit E 1mg + Calcium pantothenate 1mg + Nicotinamide 15mg + Calcium (from Dibasic Calcium Phosphate) 190mg + Phosphorus (from Dibasic Calcium Phosphate ) 150mg + Iron (from Ferrous Sulphate) 5mg + Copper (from Copper Sulphate ) 0.01mg + Iodine (from Potasium Iodide) 0.0015mg + Magnesium (from Magnesium Sulphate) 1mg + Manganese (from Manganese MUTIVITAMINS Sulphate) 0.01mg + Potasium (from Potasium Iodide) / 32 Mebocit botlle 1mg + Zinc (from Zinc Sulphate) 0.15mg MUTLIMINERAL S Starflower oil 100mg + Evening Primrose oil 100mg + Citrus bioflavonoids 10mg + Natural mixed carotenoids 2mg
Recommended publications
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Appendix on Tariff Elimination Schedule for Mercosur

    Appendix on Tariff Elimination Schedule for Mercosur

    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
  • Theophylline-7-Acetic Acid

    Theophylline-7-Acetic Acid

    Theophylline-7-acetic acid sc-237085 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Theophylline-7-acetic acid STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C9-H10-N4-O4, "purine-7-acetic acid, 1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxo-", acefylline, acephylline, 7-(carboxymethyl)theophylline, "1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxopurine-7-acetic acid", "7-theophyllineacetic acid", "7-theophyllinylacetic acid", alkaloid Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 2 Extreme=4 1 of 8 CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK Harmful if swallowed. Irritating to eyes, respiratory system and skin. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Xanthine derivatives may produce nausea, vomiting, anorexia, stomach pain, vomiting of blood and diarrhea. Protein in the urine, increased amounts of urine output, and increased excretion of renal tubular cells and red blood cells may also occur.
  • Non-Pharmacologic Therapies and Airway Clearance Techniques in Bronchiectasis

    Non-Pharmacologic Therapies and Airway Clearance Techniques in Bronchiectasis

    Division of Pulmonary, Critical Care and Sleep Medicine NON-PHARMACOLOGIC THERAPIES AND AIRWAY CLEARANCE TECHNIQUES IN BRONCHIECTASIS Ashwin Basavaraj, MD, FCCP Associate Director, NYU Bronchiectasis Program NTM Patient Education Program DC 11/24/2019 October 30, 2019 Financial Disclosure • Insmed - Consultant, Advisory Board (Active) • Hill-Rom – Consultant, Principal investigator on a clinical trial (Active) • COPD foundation grant on airway clearance 2 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 Case presentation • 66 year-old female with a history of prior pneumonia 15 years ago presents with productive cough. • She has mild shortness of breath. No fevers, no hemoptysis. She has gained two pounds over the year. • No other prior medical history, and currently not taking any medications • Initial workup including autoimmune serologies and quantitative immunoglobulin levels were negative. • You check AFB, bacterial and fungal sputum cultures. • She has 2 out 3 cultures positive for MAC. 3 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 4 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 What’s the next best step in management? A) Start 3 drug antibiotic therapy for MAC B) Initiate airway clearance with nebulized hypertonic saline and a positive expiratory pressure device C) Start antibiotics for MAC and initiate airway clearance D) Closely monitor without initiation of treatment 5 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 GOALS OF AIRWAY CLEARANCE Short term goals Long term goals • Provide more effective sputum • Reduce further airway damage by clearance that improves ventilation halting the vicious cycle • Reduce cough and breathlessness • Reduce pulmonary exacerbations • Improve quality of life O’Neill, et al.
  • Management of Breathlessness in Patients with Life Limiting Disease

    Management of Breathlessness in Patients with Life Limiting Disease

    MANAGEMENT OF BREATHLESSNESS IN PATIENTS WITH LIFE LIMITING DISEASE Helen Armstrong Dr Helen Bonwick Dr Clare Jeffries Dr Martin Ledson Dr Kate Marley Mrs Sue Oakes CURRENT STANDARDS AND GUIDELINES • Current standards and guidleines • Literature review – pharmacological and non- pharmacological • Audit results • Proposed new standards and guidelines • Current management of cough Guidelines Non pharmacological options (Level 4 ) • These are important and should not be overlooked. They may be used alone or in conjunction with medication. • They include – Reassurance and explanation – Use of fan or cool air across face – Adequate positioning of the patient to aid breathing – Breathing exercises and relaxation training – Advice on modifying lifestyle – Acupuncture, aromatherapy and reflexology Guidelines Pharmacological options Benzodiazepines (Level 3) • Benzodiazepines may be useful especially if there is coexisting anxiety and/or fear. • Lorazepam is suggested for episodes of paroxysmal breathlessness. Dose: 0.5mg-1mg sublingually as required (max dose 4mg daily). • In patients unable to tolerate oral medication or those in the dying phase, subcutaneous Midazolam 2.5mg-5mg as required may be appropriate. If effective this can be incorporated into a 24hour subcutaneous infusion via syringe driver. Guidelines Nebulised Medication (Level 4)/(Level 1) NB: The first medication of any nebulised medication, including saline, must be monitored for adverse effect such as bronchospasm. • Nebulised non opioids – Nebulised sodium chloride 0.9% may help as a mucolytic. Consider trial for 24hours. Dose: 5ml via a nebuliser 4 hourly as required. – A trial of nebulised bronchodilator should be considered if there is evidence of airways obstruction (Level 4) commonly prescribed bronchdilators are Salbutamol and Ipratropium Bromide.
  • Medicines Regulations 1984 (SR 1984/143)

    Medicines Regulations 1984 (SR 1984/143)

    Reprint as at 1 August 2011 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by section 17C of the Acts and Regulations Publication Act 1989 have been made in this reprint. A general outline of these changes is set out in the notes at the end of this reprint, together with other explanatory material about this reprint. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 August 2011 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 12 8 Advertisements for medicines 13 9 Advertisements
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Jp Xvii the Japanese Pharmacopoeia

    Jp Xvii the Japanese Pharmacopoeia

    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Acefylline Piperazine/Bambuterol Hydrochloride 1115 1 Mg of Aminophylline

    Acefylline Piperazine/Bambuterol Hydrochloride 1115 1 Mg of Aminophylline

    Acefylline Piperazine/Bambuterol Hydrochloride 1115 1 mg of aminophylline. The USP 31 specifies that ami- Oral modified-release preparations are given to children with a Preparations nophylline preparations should be labelled with respect body-weight over 40 kg in the long-term management of chronic Proprietary Preparations (details are given in Part 3) bronchospasm. An initial dose of 225 mg twice daily may be Jpn: Solfa; Neth.: Miraftil; USA: Aphthasol. to their anhydrous theophylline content. As the phar- given if the child has not previously received xanthine prepara- macokinetics of theophylline are affected by a number tions, increased after 1 week to 450 mg twice daily according to of factors including age, smoking, disease, diet, and serum-theophylline concentrations. Different modified-release Arformoterol Tartrate (USAN, rINNM) ⊗ drug interactions, the dose of aminophylline must be preparations are not considered interchangeable. carefully individualised and serum-theophylline con- Aminophylline may also be used in the management of neonatal Arformotérol, Tartrate d’; Arformoteroli Tartras; R,R-Formoterol Tartrate; Tartrato de arformoterol. (-)-N-[2-Hydroxy-5-((1R)-1- centrations monitored (see Uses and Administration of apnoea (see p.1118). Although the injection is unlicensed in the UK in children under 6 months of age, the BNFC recommends hydroxy-2-{[(1R)-2-(4-methoxyphenyl)-1-methylethyl]ami- Theophylline, p.1146). an initial dose of 6 mg/kg by intravenous injection over 20 min- no}ethyl)phenyl]formamide hydrogen (2R,3R)-2,3-dihydroxybu- In the management of acute severe bronchospasm, utes. This is followed by 2.5 mg/kg every 12 hours, increased if tanedioate. aminophylline may be given intravenously by slow in- necessary to 3.5 mg/kg every 12 hours.
  • Asthma (1 of 26)

    Asthma (1 of 26)

    Asthma (1 of 26) 1 Patient presents w/ signs & symptoms suggestive of asthma 2 3 DIAGNOSIS No ALTERNATIVE Is asthma DIAGNOSIS confi rmed? Yes ASSESS THE LEVEL OF CONTROL OF ASTHMA FOR THE PAST 4 WEEKS Controlled Partly Controlled Uncontrolled (All of the (Presence of 1-2 of these) (Presence of 3-4 of these) following) Children Adolescents Children Adolescents & ≤5 years old & Children ≤5 years old Children 6-11 years old 6-11 years old Frequency of daytime None >Few >2x/week >Few >2x/week symptoms minutes, minutes, >once a week >once a week Limitation of activities None Any Any Any Any Nocturnal waking up or None Any Any Any Any coughing due to asthma Need for reliever None >once/week >2x/week >once/week >2x/week medication* *Reliever medications taken prior to exercise excluded. Modified from: Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: Updated 2020. TREATMENT A Patient/guardian/caregiver education B Initial treatment of asthma C Management plans for long-term asthma control D Primary prevention E © Periodic assessmentMIMS & monitoring Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B13 © MIMS Pediatrics 2020 Asthma (2 of 26) 1 ASTHMA • A heterogeneous disease w/ chronic infl ammatory disorder of the airways • e most common chronic disease in pediatric age groups that causes signifi cant morbidity • Characterized by history of respiratory symptoms eg wheeze, shortness of breath, chest tightness & cough